<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39355389</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1949-8470</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>World journal of radiology</Title><ISOAbbreviation>World J Radiol</ISOAbbreviation></Journal><ArticleTitle>Behcet's disease-related panuveitis following COVID-19 vaccination: A case report.</ArticleTitle><Pagination><StartPage>460</StartPage><EndPage>465</EndPage><MedlinePgn>460-465</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4329/wjr.v16.i9.460</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Behcet's disease (BD) is an inflammatory disorder known for various symptoms, including oral and genital ulcers and ocular inflammation. Panuveitis, a severe eye condition, is rare as the first sign of BD.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">We present an unusual case of a 30-year-old man who developed panuveitis after receiving the mRNA-based coronavirus disease 2019 (COVID-19) vaccine (Moderna). Laboratory tests ruled out infections, but he had a positive HLA-B51 result and a history of genital ulcer and oral ulcers, leading to a BD diagnosis. Treatment with corticosteroids improved his condition. Interestingly, he had another episode of panuveitis after the second mRNA vaccine dose, which also responded to corticosteroids.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case highlights the rare onset of BD following mRNA COVID-19 vaccination, suggesting a potential link between these vaccines and BD's eye symptoms, emphasizing the importance of quick treatment in similar cases.</AbstractText><CopyrightInformation>©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Rou-Ting</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Education and Training, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei-Kang</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80737, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chia-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Clinical Education and Training, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Kai-Chun</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80737, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kuo-Jen</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung 81201, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yo-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80737, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung 81201, Taiwan. ycchang@kmu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Radiol</MedlineTA><NlmUniqueID>101538184</NlmUniqueID><ISSNLinking>1949-8470</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Behcet’s disease</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Ocular inflammation</Keyword><Keyword MajorTopicYN="N">Panuveitis</Keyword><Keyword MajorTopicYN="N">mRNA COVID-19 vaccine</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: All authors declare that there are no conflicts of interest for this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355389</ArticleId><ArticleId IdType="pmc">PMC11440273</ArticleId><ArticleId IdType="doi">10.4329/wjr.v16.i9.460</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, Huong DL, Piette JC, LeHoang P. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 2001;80:263–270.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491–500; discussion 500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019324</ArticleId></ArticleIdList></Reference><Reference><Citation>Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M. Behcet's disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13:57–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">27351485</ArticleId></ArticleIdList></Reference><Reference><Citation>de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287–1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867978</ArticleId><ArticleId IdType="pubmed">19790126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacherini D, Biagini I, Lenzetti C, Virgili G, Rizzo S, Giansanti F. The COVID-19 Pandemic from an Ophthalmologist's Perspective. Trends Mol Med. 2020;26:529–531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195312</ArticleId><ArticleId IdType="pubmed">32470381</ArticleId></ArticleIdList></Reference><Reference><Citation>Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297–350.</Citation><ArticleIdList><ArticleId IdType="pubmed">15967189</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkhadir K, Boutimzine N, Laghmari M, Amazouzi A, Tachfouti S, Cherkaoui O. [Prognostic factors of ocular involvement in Behçet's disease] J Fr Ophtalmol. 2019;42:612–617.</Citation><ArticleIdList><ArticleId IdType="pubmed">31088739</ArticleId></ArticleIdList></Reference><Reference><Citation>Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60:996–1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1753405</ArticleId><ArticleId IdType="pubmed">11602462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasaka Y, Hasegawa E, Keino H, Usui Y, Maruyama K, Yamamoto Y, Kaburaki T, Iwata D, Takeuchi M, Kusuhara S, Takase H, Nagata K, Yanai R, Kaneko Y, Iwahashi C, Fukushima A, Ohguro N, Sonoda KH JOIS Uveitis Survey Working Group. A multicenter study of ocular inflammation after COVID-19 vaccination. Jpn J Ophthalmol. 2023;67:14–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9684958</ArticleId><ArticleId IdType="pubmed">36417027</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581537</ArticleId><ArticleId IdType="pubmed">32756549</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, Hashimoto D, Banerji A, Li L, Anvari S, Shenoy ES. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med. 2021;384:1273–1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944952</ArticleId><ArticleId IdType="pubmed">33657292</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325:1101–1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890485</ArticleId><ArticleId IdType="pubmed">33576785</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J, Weintraub E, Shimabukuro T, Scobie HM, Moulia D, Markowitz LE, Wharton M, McNally VV, Romero JR, Talbot HK, Lee GM, Daley MF, Oliver SE. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, Hadler SC, Scobie HM, Blain AE, Moulia D, Daley MF, McNally VV, Romero JR, Talbot HK, Lee GM, Bell BP, Oliver SE. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:651–656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084127</ArticleId><ArticleId IdType="pubmed">33914723</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J. A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose. Cureus. 2022;14:e32433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833629</ArticleId><ArticleId IdType="pubmed">36644105</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>